Design, synthesis and molecular docking of novel 4-chloro-2-(4-(4-(sulfonyl)piperazin-1-yl)phenyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one for the evaluation anti-cancer activity
A series of novel 4-chloro-2-(4-(4-(sulfonyl)piperazin-1-yl)phenyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one derivatives (9a-n) were rationally designed, synthesized, and evaluated for their anticancer activity against MCF-7 and A-549 cancer cell lines. The synthesis followed a stepwise approach i...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Results in Chemistry |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211715625002474 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850213725704814592 |
|---|---|
| author | Narender Reddy Modugu Rajashekar Reddy Nimmareddy Bhimcharan Maiti Kavitha Siddoju |
| author_facet | Narender Reddy Modugu Rajashekar Reddy Nimmareddy Bhimcharan Maiti Kavitha Siddoju |
| author_sort | Narender Reddy Modugu |
| collection | DOAJ |
| description | A series of novel 4-chloro-2-(4-(4-(sulfonyl)piperazin-1-yl)phenyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one derivatives (9a-n) were rationally designed, synthesized, and evaluated for their anticancer activity against MCF-7 and A-549 cancer cell lines. The synthesis followed a stepwise approach involving crucial steps such as cyclization, esterification, reduction, benzylic bromination, Boc-protection, and the final formation of the target compounds. In vitro cytotoxicity assays revealed that six compounds (9a, 9b, 9d, 9f, 9g, and 9n) exhibited significant potency compared to the reference drug doxorubicin. Notably, compound 9a showed exceptional activity with IC50 values of 23.1 μM and 10.6 μM against A-549 and MCF-7 cells, respectively. Molecular docking studies were performed against EGFR tyrosine kinase (PDB: 4HJO) and estrogen receptor (PDB: 1ERR) to elucidate potential mechanisms of action. Compounds 9a and 9f demonstrated strong binding affinities with docking scores of 11.25 and 11.21 kcal/mol, respectively, against EGFR, and 10.41 and 10.29 kcal/mol, respectively, against estrogen receptor. A structure-activity relationship analysis revealed that electron-withdrawing and hydrophobic substituents enhanced cytotoxic efficacy. In silico ADME and toxicity predictions indicated that all compounds met Lipinski's rule of five, suggesting good oral bioavailability. These findings highlight the potential of these novel piperazinyl-pyridinone derivatives as promising anticancer agents targeting EGFR and estrogen receptor pathways. Further in vivo validation and mechanistic studies are warranted to establish their clinical relevance and optimize their pharmacological properties. |
| format | Article |
| id | doaj-art-7b556d5b9392488487f53abc2e989ae6 |
| institution | OA Journals |
| issn | 2211-7156 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Results in Chemistry |
| spelling | doaj-art-7b556d5b9392488487f53abc2e989ae62025-08-20T02:09:05ZengElsevierResults in Chemistry2211-71562025-05-011510226410.1016/j.rechem.2025.102264Design, synthesis and molecular docking of novel 4-chloro-2-(4-(4-(sulfonyl)piperazin-1-yl)phenyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one for the evaluation anti-cancer activityNarender Reddy Modugu0Rajashekar Reddy Nimmareddy1Bhimcharan Maiti2Kavitha Siddoju3Department of Chemistry Chaitanya (Deemed to be a university), Himayathnagar (v), Moinabad (M), Ranga Reddy (Dist.), Hyderabad, Telangana, India.; Aragen Life Sciences Limited, Medicinal Chemistry Division, 28a, IDA Nacharam, Hyderabad, Telangana, India.Aragen Life Sciences Limited, Medicinal Chemistry Division, 28a, IDA Nacharam, Hyderabad, Telangana, India.Aragen Life Sciences Limited, Medicinal Chemistry Division, 28a, IDA Nacharam, Hyderabad, Telangana, India.Department of Chemistry Chaitanya (Deemed to be a university), Himayathnagar (v), Moinabad (M), Ranga Reddy (Dist.), Hyderabad, Telangana, India.; Corresponding authorA series of novel 4-chloro-2-(4-(4-(sulfonyl)piperazin-1-yl)phenyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one derivatives (9a-n) were rationally designed, synthesized, and evaluated for their anticancer activity against MCF-7 and A-549 cancer cell lines. The synthesis followed a stepwise approach involving crucial steps such as cyclization, esterification, reduction, benzylic bromination, Boc-protection, and the final formation of the target compounds. In vitro cytotoxicity assays revealed that six compounds (9a, 9b, 9d, 9f, 9g, and 9n) exhibited significant potency compared to the reference drug doxorubicin. Notably, compound 9a showed exceptional activity with IC50 values of 23.1 μM and 10.6 μM against A-549 and MCF-7 cells, respectively. Molecular docking studies were performed against EGFR tyrosine kinase (PDB: 4HJO) and estrogen receptor (PDB: 1ERR) to elucidate potential mechanisms of action. Compounds 9a and 9f demonstrated strong binding affinities with docking scores of 11.25 and 11.21 kcal/mol, respectively, against EGFR, and 10.41 and 10.29 kcal/mol, respectively, against estrogen receptor. A structure-activity relationship analysis revealed that electron-withdrawing and hydrophobic substituents enhanced cytotoxic efficacy. In silico ADME and toxicity predictions indicated that all compounds met Lipinski's rule of five, suggesting good oral bioavailability. These findings highlight the potential of these novel piperazinyl-pyridinone derivatives as promising anticancer agents targeting EGFR and estrogen receptor pathways. Further in vivo validation and mechanistic studies are warranted to establish their clinical relevance and optimize their pharmacological properties.http://www.sciencedirect.com/science/article/pii/S2211715625002474AnticancerPiperazinyl-pyridinone derivativesMolecular dockingMTT assayEGFR tyrosine kinaseEstrogen receptor |
| spellingShingle | Narender Reddy Modugu Rajashekar Reddy Nimmareddy Bhimcharan Maiti Kavitha Siddoju Design, synthesis and molecular docking of novel 4-chloro-2-(4-(4-(sulfonyl)piperazin-1-yl)phenyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one for the evaluation anti-cancer activity Results in Chemistry Anticancer Piperazinyl-pyridinone derivatives Molecular docking MTT assay EGFR tyrosine kinase Estrogen receptor |
| title | Design, synthesis and molecular docking of novel 4-chloro-2-(4-(4-(sulfonyl)piperazin-1-yl)phenyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one for the evaluation anti-cancer activity |
| title_full | Design, synthesis and molecular docking of novel 4-chloro-2-(4-(4-(sulfonyl)piperazin-1-yl)phenyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one for the evaluation anti-cancer activity |
| title_fullStr | Design, synthesis and molecular docking of novel 4-chloro-2-(4-(4-(sulfonyl)piperazin-1-yl)phenyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one for the evaluation anti-cancer activity |
| title_full_unstemmed | Design, synthesis and molecular docking of novel 4-chloro-2-(4-(4-(sulfonyl)piperazin-1-yl)phenyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one for the evaluation anti-cancer activity |
| title_short | Design, synthesis and molecular docking of novel 4-chloro-2-(4-(4-(sulfonyl)piperazin-1-yl)phenyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one for the evaluation anti-cancer activity |
| title_sort | design synthesis and molecular docking of novel 4 chloro 2 4 4 sulfonyl piperazin 1 yl phenyl 2 3 dihydro 1h pyrrolo 3 4 c pyridin 1 one for the evaluation anti cancer activity |
| topic | Anticancer Piperazinyl-pyridinone derivatives Molecular docking MTT assay EGFR tyrosine kinase Estrogen receptor |
| url | http://www.sciencedirect.com/science/article/pii/S2211715625002474 |
| work_keys_str_mv | AT narenderreddymodugu designsynthesisandmoleculardockingofnovel4chloro244sulfonylpiperazin1ylphenyl23dihydro1hpyrrolo34cpyridin1onefortheevaluationanticanceractivity AT rajashekarreddynimmareddy designsynthesisandmoleculardockingofnovel4chloro244sulfonylpiperazin1ylphenyl23dihydro1hpyrrolo34cpyridin1onefortheevaluationanticanceractivity AT bhimcharanmaiti designsynthesisandmoleculardockingofnovel4chloro244sulfonylpiperazin1ylphenyl23dihydro1hpyrrolo34cpyridin1onefortheevaluationanticanceractivity AT kavithasiddoju designsynthesisandmoleculardockingofnovel4chloro244sulfonylpiperazin1ylphenyl23dihydro1hpyrrolo34cpyridin1onefortheevaluationanticanceractivity |